Genexine Counting On Hyleukin-7’s Potential As Versatile I-O Booster
Sees Future In Cell-Related Therapies
Executive Summary
Genexine’s recent M&A activity and foreign partnerships underscore its strategy on pipeline innovative therapeutics and biobetters as well as preparations to secure future growth engines, the Korean firm's vice-president tells Scrip in an interview.
You may also be interested in...
Genexine’s DNA Vaccine Shows Promise As Combo Therapy In Cervical Cancer
Genexine is poised to continue to focus on developing therapeutic DNA vaccine GX-188E as combination therapy, following Phase II interim results in advanced cervical cancer that show impressive clinical benefit over pembrolizumab monotherapy.
Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned
The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.
Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos
Argos Therapeutics lands in the hands of Genexine and SCM Lifescience after the US immunotherapy firm was put up for sale by the Delaware bankruptcy court. The Korean biotechs plan to use the company’s cGMP facilities and experience in large US Phase III trials to accelerate their global market entry.